16,567 results match your criteria prostate volume


Characteristics and progression-free survival of Afro-Caribbean men with metastatic hormone-sensitive prostate cancer at the time of diagnosis.

Prostate 2021 Jul 28. Epub 2021 Jul 28.

CHU de Pointe-à-Pitre, Univ Antilles, Univ Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail), Pointe-à-Pitre, France.

Introduction And Objectives: Metastatic hormone-sensitive prostate cancer (mHSPC) accounts for 12% of prostate cancers diagnosed in Guadeloupe according to the Guadeloupean cancer registry. Most published studies have been conducted on the Caucasian population, whereas data concerning mHSPC in the Afro-Caribbean population are lacking. We aimed to describe the patient characteristics and estimate the progression-free survival of men with mHSPC in an Afro-Caribbean population according to the available treatment. Read More

View Article and Full-Text PDF

External valıdatıon of a prostate cancer nomogram on magnetıc resonance/transrectal ultrasound fusıon bıopsy ın men wıth prıor negatıve systematıc bıopsy.

Int J Clin Pract 2021 Jul 28:e14654. Epub 2021 Jul 28.

Department of Urology, School of Medicine, Gazi University, Ankara, Turkey.

Objective: To observe how the nomogram, which was created by Truong et al., works in an independent patient group by performing external validation.

Patients And Methods: One hundred eighty-one patients who had at least one prior negative 12-core standard systematic biopsy and lesions with PI-RADS scores of 3 or higher that were detected as a result of mpMRI were included in the study. Read More

View Article and Full-Text PDF

Electrochemical sandwich-type immunosensor for the detection of PSA based on a trimetallic AgAuPt nanocomposite synthesized using the galvanic replacement reaction.

Anal Methods 2021 Jul 28. Epub 2021 Jul 28.

Chemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.

A sandwich-type electrochemical immunoassay was introduced for the determination of the prostate-specific antigen (PSA) biomarker. A direct and simple galvanic replacement reaction was performed between the Ag framework and metallic salts of tetrachloroauric(iii) acid trihydrate and chloroplatinic acid to produce a trimetallic composite of AgAuPt. The trimetallic composite of AgAuPt was applied to the preparation of the capture layer of the immunoassay for stabilizing the primary Ab at the surface of the prepared composite. Read More

View Article and Full-Text PDF

A 25-year perspective on evaluation and understanding of biomarkers in urologic cancers.

Urol Oncol 2021 Jul 24. Epub 2021 Jul 24.

Department of Urology, University of Washington, Seattle, WA.

The past 25 years have witnessed an explosion of investigative attempts to identify clinically useful biomarkers which can have meaningful impacts for patients with urologic cancers. However, in spite of the enormous amount of research aiming to identify markers with the hope of impacting patient care, only a handful have proven to have true clinical utility. Improvements in targeted imaging, pan-omics evaluation, and genetic sequencing at the tissue and single-cell levels have yielded many potential targets for continued biomarker investigation. Read More

View Article and Full-Text PDF

Deep Learning Network for Segmentation of the Prostate Gland With Median Lobe Enlargement in T2-weighted MR Images: Comparison With Manual Segmentation Method.

Curr Probl Diagn Radiol 2021 Jul 11. Epub 2021 Jul 11.

Section of Radiology - BiND, University Hospital "Paolo Giaccone", Via del Vespro 129, 90127, Palermo, Italy.

Purpose: Aim of this study was to evaluate a fully automated deep learning network named Efficient Neural Network (ENet) for segmentation of prostate gland with median lobe enlargement compared to manual segmentation.

Materials And Methods: One-hundred-three patients with median lobe enlargement on prostate MRI were retrospectively included. Ellipsoid formula, manual segmentation and automatic segmentation were used for prostate volume estimation using T2 weighted MRI images. Read More

View Article and Full-Text PDF

Urodynamic effects of prostatic urethral lift procedure for male voiding LUTS.

J Endourol 2021 Jul 27. Epub 2021 Jul 27.

Radboudumc, 6034, Urology, Nijmegen, Gelderland, Netherlands;

Aims: Primary objective is to investigate whether prostatic urethral lift (PUL) results in an improvement of urodynamic parameters that define bladder outlet obstruction (urethral resistance algorithm [URA], Schäfer grade, PdetQmax, PdetOpen).

Methods: 20 patients (main inclusion criteria: ≥ 50 years of age, BPO, IPSS ≥ 13, prostate volume ≤ 60 mL, no middle prostate lobe) were enrolled in the study and a PUL was performed. Patients underwent urodynamic investigation and filled out the IPSS and QoL before and after PUL. Read More

View Article and Full-Text PDF

A systematic review of radiation-related lymphopenia in genito-urinary malignancies.

Cancer Invest 2021 Jul 27:1-19. Epub 2021 Jul 27.

Department of Radiation Oncology, Loyola University, Chicago, IL.

Background: The impact of radiation related lymphopenia on clinical outcomes has been reported in various solid malignancies such as high grade gliomas, head and neck cancers, thoracic malignancies and gastro-intestinal malignancies but its impact is not clearly known in the context of common genito-urinary(GU) malignancies.

Methodology: To better understand the effect of radiation-associated lymphopenia in prostate and bladder cancer we undertook this systematic review of clinical studies that have studied radiation related lymphopenia in GU malignancies. A systematic methodology search of PubMed, Embase and Cochrane library resulted in 2125 abstracts. Read More

View Article and Full-Text PDF

[Primary treatment of prostate cancer using 1.5 T MR-linear accelerator].

Radiologe 2021 Jul 23. Epub 2021 Jul 23.

Klinik für Radioonkologie und Strahlentherapie, Ludwigsburg, Deutschland.

Background: Hybrid devices of MR-scanners and linear accelerators (MR-Linacs) represent a new and promising extension of radiotherapeutic options for prostate cancer. The potential advantage of magnetic resonance imaging (MRI) over computed tomography (CT) for soft tissue contrast is well-known and leads to more consistent and smaller target volumes and improved normal tissue sparing.

Objectives: This article presents an overview of clinical experience, indications, advantages and challenges of utilizing a 1. Read More

View Article and Full-Text PDF

Oligometastatic prostate cancer treatment.

Future Oncol 2021 Jul 23. Epub 2021 Jul 23.

Department of Urology & Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G Pascale Napoli, 80131, Italy.

Oligometastatic prostate cancer is an intermediate state between localized disease and widespread metastasis. Its biological and clinical peculiarities are still to be elucidated. New imaging techniques contribute to the detection of patients with oligometastatic disease. Read More

View Article and Full-Text PDF

Significance of the prostate central gland and total gland volume ratio in the diagnosis of prostate cancer patients in the prostate specific antigen grey zone.

J Int Med Res 2021 Jul;49(7):3000605211019879

Medical College of Soochow University, Suzhou, Jiangsu Province, China.

Objective: To explore the significance of the prostate central gland to total gland volume ratio (PVc/PV) in the diagnosis of prostate cancer (PCa) in patients with prostate specific antigen (PSA) levels in the grey zone (4-10 ng/ml).

Methods: This retrospective study enrolled patients that had undergone prostate biopsy. The volume of the prostate and the central prostate gland were measured. Read More

View Article and Full-Text PDF

Quantification of the uncertainties within the radiotherapy dosimetry chain and their impact on tumour control.

Phys Imaging Radiat Oncol 2021 Jul 28;19:33-38. Epub 2021 Jun 28.

Department of Chemical and Process Engineering, University of Surrey, Guildford, UK.

Background And Purpose: Dose delivered during radiotherapy has uncertainty arising from a number of sources including machine calibration, treatment planning and delivery and can impact outcomes. Any systematic uncertainties will impact all patients and can continue for extended periods. The impact on tumour control probability (TCP) of the uncertainties within the radiotherapy calibration process has been assessed. Read More

View Article and Full-Text PDF

[IMPACT OF MEMBRANOUS URETHRAL LENGTH IN DE NOVO STRESS URINARY INCONTINENCE FOLLOWING HOLMIUM LASER ENUCLEATION OF THE PROSTATE].

Nihon Hinyokika Gakkai Zasshi 2020 ;111(3):68-73

Department of Urology, Tama-Nambu Chiiki Hospital.

(Purpose) Holmium laser enucleation of the prostate (HoLEP) is widely performed in recent years; however, difficulties of surgical techniques and high frequency of postoperative stress urinary incontinence (SUI) remain as significant problems. We determined the predictive factors for de novo SUI after HoLEP. (Patients and methods) A total of 303 patients with benign prostatic hyperplasia who underwent HoLEP were retrospectively evaluated between July 2013 and April 2019. Read More

View Article and Full-Text PDF
January 2020

Early PSA kinetics for low- and intermediate-risk prostate cancer treated with definitive radiation therapy.

Pract Radiat Oncol 2021 Jul 21. Epub 2021 Jul 21.

Departments of Radiation Oncology. Electronic address:

Purpose: This study uses a patient-specific model to characterize and compare ideal PSA kinetics for low- and intermediate-risk prostate cancer following definitive radiation treatment with conventionally fractionated (CFRT), hypofractionated (HFRT), stereotactic body radiation therapy (SbRT), or brachytherapy, both high-dose-rate (HDR) and low-dose-rate (LDR).

Methods And Materials: This retrospective analysis includes low- and intermediate-risk prostate cancer patients treated between 1998 and 2018 at an NCI-designated Comprehensive Cancer Center. Demographics and treatment characteristics were prospectively collected. Read More

View Article and Full-Text PDF

Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia.

Sci Rep 2021 Jul 23;11(1):15052. Epub 2021 Jul 23.

BERG, 500 Old Connecticut Path, Building B, Framingham, MA, 01701, USA.

Prostate-specific antigen (PSA) screening for prostate cancer (PCa) is limited by the lack of specificity but is further complicated in the benign prostatic hyperplasia (BPH) population which also exhibit elevated PSA, representing a clear unmet need to distinguish BPH from PCa. Herein, we evaluated the utility of FLNA IP-MRM, age, and prostate volume to stratify men with BPH from those with PCa. Diagnostic performance of the biomarker panel was better than PSA alone in discriminating patients with negative biopsy from those with PCa, as well as those who have had multiple prior biopsies (AUC 0. Read More

View Article and Full-Text PDF

Prostate Artery Embolization Using N-Butyl Cyanoacrylate Glue for Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Valid Alternative to Microparticles?

J Clin Med 2021 Jul 17;10(14). Epub 2021 Jul 17.

Department of Interventional Radiology, Pellegrin University Hospital, Place Amélie-Raba-Léon, 33076 Bordeaux, France.

Our goal was to evaluate the feasibility, safety, and short-term outcomes of prostate artery embolization (PAE) with N-butyl cyanoacrylate (NBCA) glue as the only embolic agent in patients with benign prostatic hyperplasia (BPH)-related lower urinary tract symptoms (LUTSs). A two-center retrospective study of 50 patients (mean age, 67.6 ± 7. Read More

View Article and Full-Text PDF

A Conjugation Strategy to Modulate Antigen Binding and FcRn Interaction Leads to Improved Tumor Targeting and Radioimmunotherapy Efficacy with an Antibody Targeting Prostate-Specific Antigen.

Cancers (Basel) 2021 Jul 11;13(14). Epub 2021 Jul 11.

Department of Clinical Sciences Lund, Oncology, Lund University, 22243 Lund, Sweden.

Background: The humanized monoclonal antibody (mAb) hu5A10 specifically targets and internalizes prostate cancer cells by binding to prostate specific antigen (PSA). Preclinical evaluations have shown that hu5A10 is an excellent vehicle for prostate cancer (PCa) radiotheranostics. We studied the impact of different chelates and conjugation ratios on hu5A10's target affinity, neonatal fc-receptor interaction on in vivo targeting efficacy, and possible enhanced therapeutic efficacy. Read More

View Article and Full-Text PDF

Is Hypoxia a Factor Influencing PSMA-Directed Radioligand Therapy?-An In Silico Study on the Role of Chronic Hypoxia in Prostate Cancer.

Cancers (Basel) 2021 Jul 8;13(14). Epub 2021 Jul 8.

Department of Nuclear Medicine, Inselspital, University of Bern, 3010 Bern, Switzerland.

Radioligand therapy (RLT) targeting prostate specific-membrane antigen (PSMA) is an emerging treatment for metastatic castration-resistant prostate cancer (mCRPC). It administrates 225Ac- or 177Lu-labeled ligands for the targeted killing of tumor cells. Differently from X- or γ-ray, for the emitted α or β particles the ionization of the DNA molecule is less dependent on the tissue oxygenation status. Read More

View Article and Full-Text PDF

Three-dimensional measurement and analysis of benign prostatic hyperplasia.

Transl Androl Urol 2021 Jun;10(6):2384-2396

Department of Anatomy and Histology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.

Background: The volume and thickness of intravesical prostatic protrusion and other characteristics of benign prostatic hyperplasia have not been investigated. We determine the effects of age and prostate volume on anatomical features of benign prostatic hyperplasia using three-dimensional measurement in this study.

Methods: This retrospective study included a total of 98 patients with benign prostatic hyperplasia. Read More

View Article and Full-Text PDF

Efficacy and safety of onabotulinumtoxinA in patients with overactive bladder: subgroup analyses by sex and by serum prostate-specific antigen levels in men from a randomized controlled trial.

Int Urol Nephrol 2021 Jul 22. Epub 2021 Jul 22.

Specialty Medical and Development, GlaxoSmithKline, Tokyo, Japan.

Purpose: We aimed to assess onabotulinumtoxinA treatment outcomes by sex in patients with overactive bladder (OAB) and then explore the impact of serum prostate-specific antigen (PSA) levels in men.

Methods: Patients inadequately managed with OAB medications were randomized to receive single-dose onabotulinumtoxinA (100 U) or placebo intravesical injection in a phase III trial in Japan. We performed subgroup analyses by sex and post-hoc subgroup analyses using male PSA categories. Read More

View Article and Full-Text PDF

Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy.

JAMA Netw Open 2021 Jul 1;4(7):e2116536. Epub 2021 Jul 1.

Division of Medical Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada.

Importance: Bone resorption inhibitors (BRIs) are recommended by international guidelines to prevent skeletal-related events (SREs) among patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases. Abiraterone acetate with prednisone is currently the most common first-line therapy for the treatment of patients with mCRPC; however, the clinical impact of the addition of BRIs to abiraterone acetate with prednisone in this disease setting is unknown.

Objective: To evaluate the association of the use of concomitant BRIs with overall survival (OS) and time to first SRE among patients with mCRPC and bone metastases receiving abiraterone acetate with prednisone as first-line therapy. Read More

View Article and Full-Text PDF

Assessment of Prostate Cancer Treatment Among Black and White Patients During the COVID-19 Pandemic.

JAMA Oncol 2021 Jul 22. Epub 2021 Jul 22.

Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Importance: Early in the COVID-19 pandemic, racial/ethnic minority communities disproportionately experienced poor outcomes; however, the association of the pandemic with prostate cancer (PCa) care is unknown.

Objective: To assess the association between race and PCa care delivery for Black and White patients during the first wave of the COVID-19 pandemic.

Design, Setting, And Participants: This multicenter, regional, collaborative, retrospective cohort study compared prostatectomy rates between Black and White patients with untreated nonmetastatic PCa during the COVID-19 pandemic (269 patients from March 16 to May 15, 2020) and prior (378 patients from March 11 to May 10, 2019). Read More

View Article and Full-Text PDF

Dosimetric comparison of MR-linac-based IMRT and conventional VMAT treatment plans for prostate cancer.

Radiat Oncol 2021 Jul 21;16(1):133. Epub 2021 Jul 21.

Department of Radiation Oncology, University Hospital, LMU Munich, Marchioninistraße 15, 81377, Munich, Germany.

Background: The aim of this study was to evaluate and compare the performance of intensity modulated radiation therapy (IMRT) plans, planned for low-field strength magnetic resonance (MR) guided linear accelerator (linac) delivery (labelled IMRT MRL plans), and clinical conventional volumetric modulated arc therapy (VMAT) plans, for the treatment of prostate cancer (PCa). Both plans used the original planning target volume (PTV) margins. Additionally, the potential dosimetric benefits of MR-guidance were estimated, by creating IMRT MRL plans using smaller PTV margins. Read More

View Article and Full-Text PDF

3D deformable registration of longitudinal abdominopelvic CT images using unsupervised deep learning.

Comput Methods Programs Biomed 2021 Jul 8;208:106261. Epub 2021 Jul 8.

Department of Radiology, University of Cambridge, CB2 0QQ Cambridge, United Kingdom; Cancer Research UK Cambridge Centre, University of Cambridge, CB2 0RE Cambridge, United Kingdom; Department of Biomedical Imaging and Image-guided Therapy, Medical University Vienna, 1090 Vienna, Austria.

Background And Objectives: Deep learning is being increasingly used for deformable image registration and unsupervised approaches, in particular, have shown great potential. However, the registration of abdominopelvic Computed Tomography (CT) images remains challenging due to the larger displacements compared to those in brain or prostate Magnetic Resonance Imaging datasets that are typically considered as benchmarks. In this study, we investigate the use of the commonly used unsupervised deep learning framework VoxelMorph for the registration of a longitudinal abdominopelvic CT dataset acquired in patients with bone metastases from breast cancer. Read More

View Article and Full-Text PDF

Factors affecting urinary frequency after low-dose-rate brachytherapy for prostate cancer.

Low Urin Tract Symptoms 2021 Jul 20. Epub 2021 Jul 20.

Department of Urology, Nara Medical University, Kashihara, Japan.

Objectives: Lower urinary tract symptoms are transiently exacerbated by low-dose-rate brachytherapy (LDR-BT) for prostate cancer and recover to pretreatment levels 1 year thereafter. Generally, these symptoms are influenced by temperature. We aimed to search for factors affecting the lower urinary tract symptoms after seed implant including seasons. Read More

View Article and Full-Text PDF

The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.

Prostate 2021 Jul 20. Epub 2021 Jul 20.

Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

Background: Little is known about how benign prostatic hyperplasia (BPH) develops and why patients respond differently to medical therapy designed to reduce lower urinary tract symptoms (LUTS). The Medical Therapy of Prostatic Symptoms (MTOPS) trial randomized men with symptoms of BPH and followed response to medical therapy for up to 6 years. Treatment with a 5α-reductase inhibitor (5ARI) or an alpha-adrenergic receptor antagonist (α-blocker) reduced the risk of clinical progression, while men treated with combination therapy showed a 66% decrease in risk of progressive disease. Read More

View Article and Full-Text PDF

Rezūm for retention-retrospective review of water vaporization therapy in the management of urinary retention in men with benign prostatic hyperplasia.

Prostate 2021 Jul 20. Epub 2021 Jul 20.

Department of Urology, Westchester Medical Center, Valhalla, New York, USA.

Objective: Rezūm vapor ablation is a minimally invasive treatment for benign prostatic hyperplasia (BPH) that uses injections of sterile water vapor directly into the prostate for tissue ablation. Although Rezūm is currently indicated for use in men with prostate sizes ≥30 and ≤80 ml, it is unclear how effective Rezūm is for men in urinary retention. We sought to determine whether Rezūm is effective in the treatment of catheter-dependent urinary retention secondary to BPH. Read More

View Article and Full-Text PDF

Efficacy and efficiency of Green-Light XPS 180-watt laser system for benign prostatic enlargement in patients treated with 5α-reductase inhibitors.

Eur Rev Med Pharmacol Sci 2021 Jul;25(13):4527-4534

Department of Urology, "Sant'Andrea" Hospital, Sapienza University, Rome, Italy.

Objective: Aim of the study was to evaluate efficacy and efficiency of 180-watt Green-Light XPS (GL-XPS) laser photoselective vaporization of the prostate (PVP) in patients under 5-Alpha-Reductase Inhibitors (5ARI) treatment.

Patients And Methods: A consecutive series of patients with lower urinary tract symptoms due to benign prostatic enlargement treated by PVP with the GL-XPS were enrolled. Patients were divided in two groups according to the chronic use (>6 months) of 5ARI. Read More

View Article and Full-Text PDF

Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative.

Prostate Cancer Prostatic Dis 2021 Jul 20. Epub 2021 Jul 20.

Department of Urology, University of Michigan, Ann Arbor, MI, USA.

Background: Decipher Biopsy is a commercially available gene expression classifier used in risk stratification of newly diagnosed prostate cancer (PCa). Currently, there are no prospective data evaluating its clinical utility. We seek to assess the clinical utility of Decipher Biopsy in localized PCa patients. Read More

View Article and Full-Text PDF

Assessment of volumetric parameters derived from 68Ga-PSMA PET/CT in prostate cancer patients with biochemical recurrence: an institutional experience.

Nucl Med Commun 2021 Jul 19. Epub 2021 Jul 19.

Department of Nuclear Medicine, Ankara City Hospital, University of Health Sciences Department of Nuclear Medicine, Ankara City Hospital, Ankara Department of Nuclear Medicine, Sabuncuoğlu Şerefeddin Training and Research Hospital, University of Amasya, Amasya, Turkey.

Objective: The aim of this study was to evaluate the relationship between volumetric parameters calculated using semiautomatic quantification of lesions detected in 68Ga-labeled prostate-specific membrane antigen PET-computed tomography (68Ga-PSMA PET/CT) and clinical characteristics in prostate cancer (PCa) patients with biochemical recurrence.

Methods: A total of 85 consecutive PCa patients with biochemical recurrence who underwent 68Ga-PSMA PET/CT at our institution from January 2019 to March 2020 were retrospectively assessed. 68Ga-PSMA PET/CT-derived volumetric parameters, including whole-body PSMA tumor volume (wbPSMA-TV) and whole-body total lesion PSMA (wbTL-PSMA), as well as the established maximum and mean standardized uptake value (SUVmax and SUVmean), were calculated for each patient. Read More

View Article and Full-Text PDF

Dosimetric feasibility of stereotactic irradiation of primary prostate cancer at 5x9 Gy with a method of urethral sparing.

Br J Radiol 2021 Jul 20:20210142. Epub 2021 Jul 20.

Department of Radiation Oncology, Centre Hospitalier Lyon Sud, Pierre Benite, France.

Objective: The most commonly used dose for prostate cancer stereotactic body radiotherapy (SBRT) is 5 × 7.25 Gy. The aim of this study was to evaluate the dosimetric feasibility of a 5 × 9 Gy SBRT regimen while still limiting the dose to the urethra to 5 × 7. Read More

View Article and Full-Text PDF